3 Nov 2014 10:26
3 November 2014
Silence Therapeutics plc
Additional listing
Silence Therapeutics plc, AIM: SLN, ('the Company'), announces that it has issued 48,667 new ordinary shares of 5p each ("Ordinary Shares") following the exercise of share options under the Employee Share Scheme.
Application has been made for the 48,667 Ordinary Shares issued to be admitted to trading on AIM ("Admission"). Admission is expected to take place on Friday, 7 November 2014. The Ordinary Shares shall rank pari passu with the existing ordinary shares in the Company.
The total number of shares in issue, following admission, will be 52,098,109.
Enquiries:
Silence Therapeutics plc | +44 (0)20 3700 9711 |
Timothy Freeborn, Finance Director & Company Secretary | |
Rozi Morris, Communications Manager | |
Canaccord Genuity Limited | +44 (0)20 7523 8350 |
Lucy Tilley/Dr Julian Feneley/Henry Fitzgerald-O'Connor |
About Silence Therapeutics plc (www.silence-therapeutics.com)
Silence Therapeutics is a leading RNA interference (RNAi) or 'gene silencing' platform technology company which has proprietary delivery systems. Combined, the RNAi and delivery platforms enable the development of multiple products to multiple drug targets allowing the development of novel therapeutics for diseases with high unmet medical need.
Silence is one of only a handful of listed companies globally which has human validated RNA delivery technology. Its platform is one of the safest and most tested, with over 400 patients dosed and no immune response observed so far. Silence's RNAi platform has been used in three Phase 2 clinical trials, two awaiting results. It also has a robust IP estate protecting its proprietary technology.